ReviewPLoS neglected tropical diseases2024
Progress interrogating TRPMPZQ as the target of praziquantel.
Review in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Direct measurement ofbioRxiv : the preprint server for biology · 2026Article
- Extensive parasite transmission and variation in a functional receptor associated with drug resistance in endemicScience advances · 2026Article
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Evaluation of the antiparasitic efficacy of praziquantel against Prohemistomum vivax (Cyathocotylidae) metacercariae in naturally infected African catfish (Clarias gariepinus).Scientific reports · 2026Article
- Novel 1ACS infectious diseases · 2026Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMInternational journal for parasitology. Drugs and drug resistance · 2026Article
- Resistance evaluation and surveillance initiative for schistosomiasis treatment: study protocol for the RESIST project.BMC infectious diseases · 2026Article
- Long-term persistence ofCurrent research in parasitology & vector-borne diseases · 2026Article
- Target-Based Design of Praziquantel Analogs at Cestode TRPMACS infectious diseases · 2025Article
- Species-specific detection of Schistosoma japonicum using the 'SNAILS' DNA-based biosensor.Communications biology · 2025Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMbioRxiv : the preprint server for biology · 2025Article
- Structural Insights and Calcium-Switching Mechanism ofInternational journal of molecular sciences · 2025Article
- Article
- UPLC-MS/MS method for simultaneous determination of pyrantel, praziquantel, febantel, fenbendazole and oxfendazole in dog plasma and its application to a bioequivalence study.Frontiers in pharmacology · 2025Article
- TRP drop, TRP drop: a steady patter of anti-schistosomal target illumination.Frontiers in parasitology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The drug praziquantel (PZQ) has served as the long-standing drug therapy for treatment of infections caused by parasitic flatworms. These encompass diseases caused by parasitic blood, lung, and liver flukes, as well as various tapeworm infections. Despite a history of clinical usage spanning over 4 decades, the parasite target of PZQ has long resisted identification. However, a flatworm transient receptor potential ion channel from the melastatin subfamily (TRPMPZQ) was recently identified as a target for PZQ action. Here, recent experimental progress interrogating TRPMPZQ is evaluated, encompassing biochemical, pharmacological, genetic, and comparative phylogenetic data that highlight the properties of this ion channel. Various lines of evidence that support TRPMPZQ being the therapeutic target of PZQ are presented, together with additional priorities for further research into the mechanism of action of this important clinical drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.